These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21160143)

  • 1. Specific congenital malformations after exposure to cyclophosphamide, epirubicin and 5-fluorouracil during the first trimester of pregnancy.
    Leyder M; Laubach M; Breugelmans M; Keymolen K; De Greve J; Foulon W
    Gynecol Obstet Invest; 2011; 71(2):141-4. PubMed ID: 21160143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer.
    Andreadis C; Charalampidou M; Diamantopoulos N; Chouchos N; Mouratidou D
    Gynecol Oncol; 2004 Oct; 95(1):252-5. PubMed ID: 15385141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for breast cancer during pregnancy.
    Mathelin C; Annane K; Dufour P; Liegeois P; Bergerat JP
    Eur J Obstet Gynecol Reprod Biol; 2005 Dec; 123(2):260-2. PubMed ID: 16024158
    [No Abstract]   [Full Text] [Related]  

  • 4. Neonatal effects of breast cancer chemotherapy administered during pregnancy.
    Kerr JR
    Pharmacotherapy; 2005 Mar; 25(3):438-41. PubMed ID: 15843292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
    Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
    J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful pregnancy outcome with 5-flurouracil, epirubicin, cyclophosphamide chemotherapy, and hemostatic radiotherapy with abdominal shielding for metastatic invasive intraductal breast carcinoma.
    Sharma JB; Pushparaj M; Kumar S; Roy KK; Raina V; Malhotra N
    Arch Gynecol Obstet; 2009 Mar; 279(3):415-7. PubMed ID: 18642013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer].
    Hui R; Zhang M; Hao XM; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):871-4. PubMed ID: 18396651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
    J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals.
    Ring AE; Smith IE; Jones A; Shannon C; Galani E; Ellis PA
    J Clin Oncol; 2005 Jun; 23(18):4192-7. PubMed ID: 15961766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA damage in peripheral blood lymphocytes in patients during combined chemotherapy for breast cancer.
    Sánchez-Suárez P; Ostrosky-Wegman P; Gallegos-Hernández F; Peñarroja-Flores R; Toledo-García J; Bravo JL; Del Castillo ER; Benítez-Bribiesca L
    Mutat Res; 2008 Apr; 640(1-2):8-15. PubMed ID: 18207203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of manic episode during treatment with 5-fluorouracil, epirubicin and cyclophosphamide for breast cancer.
    Pacchiarotti I; Mazzarini L; Pellegrini P; Venturelli V; Sani G; Sánchez-Moreno J; Mancinelli I; Tatarelli R; Kotzalidis GD; Girardi P
    Gen Hosp Psychiatry; 2007; 29(5):461-3. PubMed ID: 17888816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy and concomitant irradiation in inflammatory breast cancer.
    Tubiana-Mathieu N; Lejeune C; Bonnier P; Genet D; Adjadj DJ; Berda JF; Muracciole X; Delaby F; Clavere P; Benyoub A; Rhein B; Juin B; Piana L
    Anticancer Res; 2001; 21(4B):3061-7. PubMed ID: 11712811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
    Kimura M; Tominaga T; Takatsuka Y; Toi M; Abe R; Koyama H; Takashima S; Nomura Y; Miura S; Kimijima I; Tashiro H; Ohashi Y;
    Breast Cancer; 2010 Jul; 17(3):190-8. PubMed ID: 19575284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
    J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero.
    Hahn KM; Johnson PH; Gordon N; Kuerer H; Middleton L; Ramirez M; Yang W; Perkins G; Hortobagyi GN; Theriault RL
    Cancer; 2006 Sep; 107(6):1219-26. PubMed ID: 16894524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
    Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
    Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
    Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Burkitt's lymphoma during pregnancy.
    Lam MS
    Ann Pharmacother; 2006 Nov; 40(11):2048-52. PubMed ID: 17062832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-eclampsia following chemotherapy for breast cancer during pregnancy: case report and review of the literature.
    Massey Skatulla L; Loibl S; Schauf B; Müller T
    Arch Gynecol Obstet; 2012 Jul; 286(1):89-92. PubMed ID: 22395860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.